April 21 (Reuters) - Merck and Eisai's experimental combination treatments failed to significantly improve survival or reduce ...
Merck & Co (MSD) and Eisai’s combination therapies failed to meet the dual primary endpoints of progression-free survival ...
Zacks Investment Research on MSN
MRK down as triplet therapy fails to meet goal in kidney cancer study
Merck MRK, along with its partner Eisai, announced that the phase III LITESPARK-012 study, which evaluated Keytruda-based ...
After prevailing in two kidney cancer trials in the refractory and early-stage settings, Merck & Co.’s blockbuster prospect ...
A triplet regimen comprising Merck’s Welireg and PD-1 blockbuster Keytruda and Eisai’s Lenvima flopped in a Phase 3 renal ...
Beyond traditional monitoring of kidney transplant recipients, donor derived-cell free DNA may permit early identification of graft damage.
Naomi Haas, MD, from the Hospital at the University of Pennsylvania, explains that most trials regarding neoadjuvant therapy ...
KEYTRUDA is currently approved as adjuvant monotherapy and in combination regimens for appropriate patients with RCC in the U.S., European Union (EU), Japan and other countries around the world. For ...
For patients with primary localized renal cell carcinoma (RCC), especially those who aren’t good candidates for surgery, noninvasive or minimally invasive ablative treatments have emerged as important ...
In a recent study, mean sensitivity was 85.5% and specificity 87% for detection of clear-cell renal cell carcinoma. (HealthDay News) — ⁸⁹Zr-labeled monoclonal antibody ([⁸⁹Zr]Zr-girentuximab) for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results